

## Increased mortality associated with borderline pulmonary hypertension: Insights from The National Echocardiography Database of Australia

Geoff Strange<sup>a</sup>, PhD FCSANZ, Simon Stewart<sup>b</sup>, PhD FESC FAHA, David S Celermajer<sup>c</sup>, David Prior<sup>d</sup>, Greg Scalia<sup>e</sup>, Tom Marwick<sup>f</sup>, Eli Gabbay<sup>a</sup>, Marcus Ilton<sup>g</sup>, Majo Joseph<sup>h</sup>, Jim Codde<sup>a</sup> and David Playford<sup>a</sup> on behalf of the NEDA contributing sites

---

### Author Affiliations:

University of Notre Dame, Fremantle<sup>a</sup>; University of Cape Town<sup>b</sup>; Faculty of Medicine and Health, University of Sydney,<sup>c</sup>; University of Melbourne,<sup>d</sup> St Vincent's Hospital, Melbourne<sup>d</sup>; University of QLD, The Prince Charles Hospital, Brisbane<sup>e</sup>; Baker IDI Heart and Diabetes Institute, Melbourne<sup>f</sup> Menzies School of Health Research, Royal Darwin Hospital<sup>g</sup>; Flinders University, Adelaide<sup>h</sup>.

**BACKGROUND:** There is increasing evidence that current thresholds for diagnosing pulmonary hypertension (PHT), underestimate the prognostic impact of sub-clinical/borderline PHT.

**OBJECTIVES:** To determine the prognostic impact of increasing pulmonary pressures within the National Echocardiography Database of Australia (NEDA) cohort (N=313,492).

**METHODS:** We extracted echocardiographic data from NEDA. The distribution of measurable, estimated right ventricular systolic pressures (eRVSP) were examined in 157,842 men and women. All had data-linkage to long-term survival during median follow-up of 1,543, (IQR 799, 2720) days. The relationship between eRVSP and long-term mortality were then examined.

**RESULTS:** The cohort comprised 74,505 men and 83,437 women aged 65.6±17.7 years. Overall, 17,955 (11.4%), 7,016 (4.4%) and 4,515 (2.9%) individuals had eRVSP levels indicative of mild (40-49 mmHg), moderate (50-59 mmHg) or severe PHT (≥60 mmHg), respectively. As expected, these individuals were more likely to die during long-term follow up

(adjusted HR 9.73, 95% CI 8.60 – 11.0 for severe PHT;  $p < 0.001$ ). After adjustment for age, sex and evidence of left heart disease, a clear threshold of increased mortality equating to borderline PHT was also found: those individuals with eRVSP levels within the 3<sup>rd</sup> (28.05 to 32.0 mmHg – HR 1.410, 95% CI 1.310 to 1.517) and 4<sup>th</sup> (32.05 to 38.83 mmHg – HR 1.979, 95% 1.853 to 2.114) quintile distribution, having significantly higher mortality ( $p < 0.001$ ) than the lowest quintile.

**CONCLUSIONS:** In the large and unique NEDA cohort, we not only confirmed the prognostic impact of clinically accepted levels of PHT, but also identified a distinctly lower threshold for increased risk of mortality (eRVSP >30mmHg) indicative of borderline PHT.